Table 4.
Comparison between patients with diarrhea and those without diarrhea during nintedanib treatment for idiopathic pulmonary fibrosis and risk factors for diarrhea.
| Characteristics | Overall | No | Yes | Monovariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | ||||
| 77 | 50 | 27 | |||||||
| Age | 1.540 | 0.205–1.434 | 0.215 | ||||||
| ≤74 | 44 | 26 | 18 | ||||||
| ≥75 | 33 | 24 | 9 | ||||||
| Sex | 1.393 | 0.137–1.658 | 0.238 | ||||||
| Female | 12 | 6 | 6 | ||||||
| Male | 65 | 44 | 21 | ||||||
| Smoking history | 0.389 | 0.107–1.420 | 0.144 | ||||||
| No | 11 | 5 | 6 | ||||||
| Yes | 66 | 45 | 21 | ||||||
| PS | 2.438 | 0.880–6.749 | 0.082 | 1.564 | 0.381–6.507 | 0.531 | |||
| 0–1 | 56 | 39 | 16 | ||||||
| 2–4 | 21 | 11 | 11 | ||||||
| mMRC | 1.768 | 0.660–4.768 | 0.255 | 1.171 | 0.260–5.265 | 0.837 | |||
| 0–1 | 52 | 36 | 16 | ||||||
| 2–4 | 25 | 14 | 11 | ||||||
| GAP Index | 6.241 | 1.277–9.019 | 0.012 | 1.829 | 0.546–6.127 | 0.328 | |||
| ≤5 | 46 | 35 | 11 | ||||||
| ≥6 | 31 | 15 | 16 | ||||||
| BMI | 4.432 | 1.611–12.191 | 0.003 | 3.460 | 1.044–11.467 | 0.042 | |||
| <21.6 | 52 | 39 | 12 | ||||||
| ≥21.6 | 25 | 11 | 15 | ||||||
| PSL combination | 0.240 | 0.072–0.798 | 0.015 | 0.241 | 0.059–0.995 | 0.049 | |||
| No | 52 | 29 | 23 | ||||||
| Yes | 25 | 21 | 4 | ||||||
| Nintedanib dose | 1.286 | 0.468–3.532 | 0.626 | 1.170 | 0.321–4.265 | 0.812 | |||
| 300 mg/day | 54 | 36 | 18 | ||||||
| 200 mg/day | 23 | 14 | 9 | ||||||
OR: odds ratio, CI: confidence interval, PS: performance status, mMRC: modified Medical Research Council Dyspnea Scale, BMI: body mass index, PSL: prednisolone.